Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/9/2008

Keryx to Host Investor Conference Call on Monday, May 12, 2008 at 8:30am

EDT

NEW YORK, May 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the first quarter ended March 31, 2008.

At March 31, 2008, the Company had cash, cash equivalents, investment securities, interest receivable and license receivable of $47.6 million, as compared to $64.7 million at December 31, 2007. In April 2008, we received a payment of $8.0 million that was classified as a license receivable at March 31, 2008. The payment was made pursuant to the September 2007 licensing agreement among Keryx, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

The net loss for the first quarter ended March 31, 2008 was $34,536,000, or $0.79 per share, compared to a net loss of $21,813,000, or $0.50 per share, for the first quarter in 2007, representing an increase in net loss of $12,723,000. The increase in net loss was primarily attributable to costs associated with the cessation of our development of Sulonex. Such costs included an $11,037,000 non-cash impairment charge related to the write-down of the assets of the Sulonex manufacturing suite to their estimated fair value, and a $2,063,000 provision for estimated costs relating to the required restoration of the manufacturing facility to its original condition, partially offset by a decrease of $2,264,000 in non-cash compensation expense, primarily related to stock options and restricted
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2008)...NEAPOLIS, July 3 /- The Eniva Researc...g by the world-famous Linus Pauling,Micronutrient ...h,demonstrated the Eniva Health Supplement VIBE(R)...for human cells. This third party testing was,perf...o further identify,mechanisms by which the Eniva V...
(Date:7/3/2008)...SISSAUGA, ON, July 3 / Vaso...that it has implemented additional,restructuring p...iously,announced, the Company has been exploring s...cquisitions and mergers. In conjunction with this,...ve review of its VP,series of drugs, and has deter...
(Date:7/3/2008)... BRUNSWICK, N.J., July 3 /-...pany") (Amex: SNT ) announced today,that it has c...ance) to,supply Polyplus,s "in vivo-jetPEI" for sy...f siRNA against Factor 5A and a plasmid of the Fac...itive preclinical in vivo results,using its combin...
(Date:7/3/2008)...INE, Calif., July 3 /- Antigen Discov....), a leader in high throughput,antigen/biomarker ...ools,announced today that the Company was awarded...lergy and Infectious Diseases (NIAID) and the,Nati...million grant will,fund efforts to further develop...
Breaking Biology Technology:Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2Vasogen Provides Corporate Update 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 4Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development 2
...he July 2006 edition of MedAd News sustains that...r. On Aug, 23, 2004, I wrote an article for this p...o, Boston, Geneva, or Chicago? " , ,In this articl... dates and commercial milestones that date the ind...tech and Amgen went public (1980). The authors of ...
...ral and man-made disasters, a Wisconsin truck manu...red business network. , ,The purchase will outfit ...cated networking solutions, including a single con... five years. , ,The solutions, provided by AT&T, ...ns companies, are intended to help preserve "missi...
...scles to focus on different distances. Man-made de...e sensors do not require these external controls. ...ison College of Engineering are investigating a l...ironmental changes and could be used in a variety ...nostic tools and life science sensor arrays. , ,Th...
... a crucial moment in the development of stem cell ...ers of human embryonic stem cell research to bring...this fall. , ,Doyle, speaking at a symposium of th...ink thank, said the reason the nation is at a crit...ant to see stem cell research stopped in it tracks...
Other Biology Technology:At 30, biotech is an industry at a crossroads 2At 30, biotech is an industry at a crossroads 3At 30, biotech is an industry at a crossroads 4At 30, biotech is an industry at a crossroads 5At 30, biotech is an industry at a crossroads 6At 30, biotech is an industry at a crossroads 7"Smart" lenses hold commercial potential 2Doyle says practical politics must advance embryonic stem cell research 2Doyle says practical politics must advance embryonic stem cell research 3
(Date:7/2/2008)...team has published the first clear example of how ...seases that are normally tolerated singly may conv..., In a report issued June 25 by PLoS ONE, an on...xamined outbreaks of canine distemper virus (CDV) ...ortality in Serengeti lions. CDV cycles periodical...
(Date:7/2/2008)...2, 2008) Led by a bold commitment from Germany, l...pportunity at the upcoming G8 Summit in Japan to t...te change. , German Chancellor Angela Merkel,s r...to conserve tropical forests, followed by increase...address a major source of greenhouse gas emissions...
(Date:7/2/2008)...ished online in The FASEB Journal provide more e...r intelligence can improve. According to MIT scien...foods from infant formula to eggs increase brain s...pe human brains will, like those of experimental a...g more brain synapses and thus restoring cognitive...
(Date:7/2/2008)... Florida State University faculty member who uses ...f cancer-killing drugs is attracting worldwide att...an assistant professor of chemical and biomedical ...State University College of Engineering, is using ... known as recombinant immunotoxins can best be mod...
Breaking Biology News(10 mins):G8 summit: Opportunity for immediate action on climate change 2G8 summit: Opportunity for immediate action on climate change 3FSU researcher using computers to hone cancer-fighting strategies 2Diabetic Food Shopping That Wont Break a Budget 16645 1Diabetic Food Shopping That Wont Break a Budget 16645 2Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer 16643 1Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer 16643 2Male Contraception 3A Progress Slow but Steady 16640 1Male Contraception 3A Progress Slow but Steady 16640 2Male Contraception 3A Progress Slow but Steady 16640 3National hospice study reveals gaps in service 16638 1National hospice study reveals gaps in service 16638 2National hospice study reveals gaps in service 16638 3National hospice study reveals gaps in service 16638 4
... embryos for genetic diseases during in vitro fert...lthy child, but a genetic glitch could potentially...them, University of Florida researchers say. , Ci...n genetic diagnosis, the method many practitioners... researchers set out to study the procedure. Their...
... cells that develop in the olfactory system of adu...nt from that of older neurons. The new olfactory ... preferentially learning to respond to new odors. ...y-generated neurons could be induced to adapt to a...aps allowing them to replace neurons lost to injur...
...Mukhopadhyay and Eric Johnson from the Virginia Bi...vered a novel enzyme that represents an ancient de...elopment of early metabolism on earth. , The resea...nal of Biological Chemistry, in the article "A New...dependent Enzyme, from the Methanoarchaeon Methano...
...s, the ability to accurately sense light governs e...d pigmentation to patterns of growth and flowering...ned a detailed map of one of biology,s most import...es across life,s plant, fungal, and bacterial king... of the protein known as phytochrome, scientists c...
Other Biology News:Genetic testing still smart choice, despite uncertainties 2Genetic testing still smart choice, despite uncertainties 3Neurons generated in the adult brain learn to respond to novel stimuli 2Novel protein complex enables survival in hostile environment 2Novel protein complex enables survival in hostile environment 3Novel protein complex enables survival in hostile environment 4Novel protein complex enables survival in hostile environment 5Scientists map one of biology's critical light-sensing structures 2Scientists map one of biology's critical light-sensing structures 3
...ector Sequencing Primer is designed for sequencing...s (Cat.# V2031, V2051, V2061). The primer hybridiz...25343, approximately 4050 base pairs upstream of t...rmine if an insert is cloned in-frame with the bio...
The versatile Zymo-Spin I-96 Plate can be used either in centrifuges or on vacuum manifolds for the large-scale (i.e., 96-well) purification of DNA and/or RNA. Its deep-well, durable polypropylene co
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin:
...he first all-inclusive collection of key procedure.... Methods developed by the leaders in Pichia expre...cols. This book will guide you from choosing the a...ruction and analysis, to production of your protei...
Biology Products: